Harry Akza Putrawan, Irfan Idris, Arif Santoso, Harun Iskandar, Zainul Muttaqin, Jamal Zaini, Rosdiana Natzir, Uleng Bahrun, Suryani Tawali
{"title":"评估小母亲抗十足瘫3和转化生长因子β水平与治疗后肺结核患者肺纤维化和功能的关系。","authors":"Harry Akza Putrawan, Irfan Idris, Arif Santoso, Harun Iskandar, Zainul Muttaqin, Jamal Zaini, Rosdiana Natzir, Uleng Bahrun, Suryani Tawali","doi":"10.4103/ijmy.ijmy_60_25","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Tuberculosis (TB) is a significant global health issue, with posttreatment fibrosis negatively affecting pulmonary function and patient quality of life. This research investigated the processes driving post-TB pulmonary fibrosis and its impact on patients.</p><p><strong>Methods: </strong>This research involved a cohort of 38 pulmonary TB patients undergoing intensive treatment for 2 months. Transforming Growth Factor Beta (TGFβ) and Small Mothers Against Decapentaplegic 3 (SMAD3) levels were quantified pre- and posttreatment using the Enzyme Linked Immuno Sorbent Assay method. Fibrosis was evaluated via thoracic imaging, and lung function was assessed through spirometry.</p><p><strong>Results: </strong>TGFβ and SMAD3 levels were decreased post-treatment (P = 0.03 and P = 0.01). A significant association existed between postintervention SMAD3 levels and the occurrence of fibrosis (P = 0.03) and diminished lung function (P = 0.01). Receiver operating characteristic analysis indicated that post-intervention SMAD3 exhibited an area under the curve of 0.8, with a sensitivity of 87% and specificity of 71%, suggesting its potential as a biomarker for fibrosis.</p><p><strong>Conclusion: </strong>Levels of TGFβ and SMAD3 following pulmonary TB treatment are linked to fibrosis and reduced lung function. SMAD3 post-intervention may be a fibrosis biomarker in pulmonary TB patients.</p>","PeriodicalId":14133,"journal":{"name":"International Journal of Mycobacteriology","volume":"14 3","pages":"239-245"},"PeriodicalIF":1.5000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evaluation of Small Mothers against Decapentaplegic 3 and Transforming Growth Factor Beta Levels in Relation to Lung Fibrosis and Function in Treated Pulmonary Tuberculosis Patients.\",\"authors\":\"Harry Akza Putrawan, Irfan Idris, Arif Santoso, Harun Iskandar, Zainul Muttaqin, Jamal Zaini, Rosdiana Natzir, Uleng Bahrun, Suryani Tawali\",\"doi\":\"10.4103/ijmy.ijmy_60_25\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Tuberculosis (TB) is a significant global health issue, with posttreatment fibrosis negatively affecting pulmonary function and patient quality of life. This research investigated the processes driving post-TB pulmonary fibrosis and its impact on patients.</p><p><strong>Methods: </strong>This research involved a cohort of 38 pulmonary TB patients undergoing intensive treatment for 2 months. Transforming Growth Factor Beta (TGFβ) and Small Mothers Against Decapentaplegic 3 (SMAD3) levels were quantified pre- and posttreatment using the Enzyme Linked Immuno Sorbent Assay method. Fibrosis was evaluated via thoracic imaging, and lung function was assessed through spirometry.</p><p><strong>Results: </strong>TGFβ and SMAD3 levels were decreased post-treatment (P = 0.03 and P = 0.01). A significant association existed between postintervention SMAD3 levels and the occurrence of fibrosis (P = 0.03) and diminished lung function (P = 0.01). Receiver operating characteristic analysis indicated that post-intervention SMAD3 exhibited an area under the curve of 0.8, with a sensitivity of 87% and specificity of 71%, suggesting its potential as a biomarker for fibrosis.</p><p><strong>Conclusion: </strong>Levels of TGFβ and SMAD3 following pulmonary TB treatment are linked to fibrosis and reduced lung function. SMAD3 post-intervention may be a fibrosis biomarker in pulmonary TB patients.</p>\",\"PeriodicalId\":14133,\"journal\":{\"name\":\"International Journal of Mycobacteriology\",\"volume\":\"14 3\",\"pages\":\"239-245\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Mycobacteriology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/ijmy.ijmy_60_25\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/9/15 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Mycobacteriology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ijmy.ijmy_60_25","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/15 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Evaluation of Small Mothers against Decapentaplegic 3 and Transforming Growth Factor Beta Levels in Relation to Lung Fibrosis and Function in Treated Pulmonary Tuberculosis Patients.
Introduction: Tuberculosis (TB) is a significant global health issue, with posttreatment fibrosis negatively affecting pulmonary function and patient quality of life. This research investigated the processes driving post-TB pulmonary fibrosis and its impact on patients.
Methods: This research involved a cohort of 38 pulmonary TB patients undergoing intensive treatment for 2 months. Transforming Growth Factor Beta (TGFβ) and Small Mothers Against Decapentaplegic 3 (SMAD3) levels were quantified pre- and posttreatment using the Enzyme Linked Immuno Sorbent Assay method. Fibrosis was evaluated via thoracic imaging, and lung function was assessed through spirometry.
Results: TGFβ and SMAD3 levels were decreased post-treatment (P = 0.03 and P = 0.01). A significant association existed between postintervention SMAD3 levels and the occurrence of fibrosis (P = 0.03) and diminished lung function (P = 0.01). Receiver operating characteristic analysis indicated that post-intervention SMAD3 exhibited an area under the curve of 0.8, with a sensitivity of 87% and specificity of 71%, suggesting its potential as a biomarker for fibrosis.
Conclusion: Levels of TGFβ and SMAD3 following pulmonary TB treatment are linked to fibrosis and reduced lung function. SMAD3 post-intervention may be a fibrosis biomarker in pulmonary TB patients.